Uncategorized

Based on global ALEX, has crizotinib been relegated to the therapeutic scrapheap when it comes to patients with ALK rearrangements? Or does it retain some role? The global ALEX study, […]

Please give us a global perspective on the results of global ALEX. Will alectinib definitively displace crizotinib or ceritinib as the first-line treatment for ALK-rearranged non-small cell lung cancer (NSCLC)? […]

Posted: June 2017 By Keightley Amen, BA, ELS In 2015, the International Association for the Study of Lung Cancer (IASLC) and the European Society for Medical Oncology (ESMO) established an […]

Posted: June 2017 Long-term IASLC member Bruce E. Johnson, MD, will serve as the 2017– 2018 President of the American Society of Clinical Oncology (ASCO) upon the conclusion of the […]

Posted: February 2017 By Lori Alexander, MTPW, ELS, MWC The closing plenary session at IASLC WCLC 2016 featured several highly regarded oncologists who have devoted the greater part of their […]

Posted: February 2017 From the Editor / Corey J. Langer, MD, FACP A new year has dawned, and with it both excitement and uncertainty in the field of thoracic oncology. […]

By Edgardo S. Santos Castillero, MD, and Roberto I. Lopez, MD In August 2016, the 7th Latin America Conference on Lung Cancer (LALCA) was held in Panama City, Republic of […]

On September 14, Eli Lilly and Company announced the retirement effective January 1, 2017, of Richard B. Gaynor, MD, senior vice president, Global Development & Medical Affairs for Lilly’s Oncology […]

The Victorian Comprehensive Cancer Centre, which opened this summer, is a new purpose-built facility for cancer research, treatment, care, and education in Melbourne’s Parkville biomedical precinct. In addition to the […]

By: Corey J. Langer, MD, FACP Professor of Medicine University of Pennsylvania Editor, IASLC Lung Cancer News Welcome to the second issue of IASLC Lung Cancer News. In concert with the […]